ClinicalTrials.gg
CompletedNCT00651612Updated Apr 3, 2008

Study to Evaluate Safety of Brimonidine/Timolol Fixed Combination in Glaucoma or Ocular Hypertension Patients

A Phase 3 interventional study of Brimonidine 0.2%/Timolol 0.5% Fixed Combination Ophthalmic Solution and Concurrent brimonidine 0.2% and 0.5% timolol in Glaucoma and Ocular Hypertension, sponsored by Allergan. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2008-04-03.

Sponsored by Allergan (part of AbbVie) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
604
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 23 studies testing brimonidine in Glaucoma — 1 open to participants now, 1 under way, none of them phase 3. brimonidine · Glaucoma.

Enrollment
Largest of 21
604 · median 56
Started
2005
with 1 other
Phase 3
3 of 23
none open now
Registered
9th of 23
by date
Lead sponsor
5 of 23
Allergan

Among the 23 studies testing brimonidine in Glaucoma, this one has the largest enrollment of the 21 interventional ones that give a count, is one of 2 that started in 2005, is one of 3 in phase 3, and was the 9th registered.

Glaucoma

1,419 studies on the registry are indexed under Glaucoma; 220 are open to participants now.

Browse Glaucoma studies →

Open to participants now

1 of the 23 studies testing brimonidine in Glaucoma is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About brimonidine

brimonidine: first FDA approval 1996 (ALPHAGAN), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 154 Glaucoma studies recruiting now, 112 (73%) set no upper age limit and 9 (6%) stop at 75 or younger; 13 take children under 18; 44 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 23 studies testing brimonidine in Glaucoma, or all of them as a file.
02

Study summary

This study evaluates the safety of brimonidine/timolol fixed combination in glaucoma or ocular hypertension patients

03

Conditions studied

  • Glaucoma
  • Ocular Hypertension
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of ocular hypertension or glaucoma
  • Patient requires IOP-lowering therapy in both eyes

Exclusion criteria

Exclusion Criteria:

  • Uncontrolled medical conditions
  • to β-adrenoceptor antagonist therapy or brimonidine therapy
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
604 participants (actual)

Study arms

  • Experimental
    1

    Brimonidine 0.2%/Timolol 0.5% Fixed Combination Ophthalmic Solution

    Drug: Brimonidine 0.2%/Timolol 0.5% Fixed Combination Ophthalmic Solution

  • Active comparator
    2

    Concurrent Brimonidine 0.2% and 0.5% Timolol

    Drug: Concurrent brimonidine 0.2% and 0.5% timolol

Interventions

  • DrugBrimonidine 0.2%/Timolol 0.5% Fixed Combination Ophthalmic Solution

    Drug page: Brimonidine

    Brimonidine 0.2%/timolol 0.5% fixed combination ophthalmic solution 1 drop instilled in each eye two times daily (morning and evening)

    Also known as: COMBIGAN™

  • DrugConcurrent brimonidine 0.2% and 0.5% timolol

    Brimonidine 0.2%, 1 drop instilled in each eye three times daily (morning, afternoon, and evening) and timolol 0.5% timolol, 1 drop instilled in each eye twice daily (morning and evening) and vehicle of brimonidine combination ophthalmic solution 1 drop instilled in each eye (morning, afternoon and/or evening)

06

What researchers measure

Primary outcomes

  1. Adverse Events

    Time frame: Day 10

07

Study locations

1 site
  • Newport Beach, California, United States
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2005, a primary completion of Jan 2007 and a completion of Jan 2007. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 1, 2008
First posted
Apr 3, 2008
Start
Nov 2005
Primary completionActual
Jan 2007
CompletionActual
Jan 2007
Last update
Apr 3, 2008
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 3, 2008, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00651612
Lead sponsor
Allergan
First posted
Apr 3, 2008
Start date
Nov 2005
Primary completion
Jan 2007
Completion
Jan 2007
Last update
Apr 3, 2008

Study contacts

Medical Director
study director · Allergan
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2008. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Brimonidine

Start the discussion